ClinicalTrials.gg
CompletedNCT06267560Updated Aug 10, 2026

Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

A Phase 3 interventional study of TQJ230 and Placebo in Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease, sponsored by Novartis Pharmaceuticals. Completed at 96 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
422
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) 80 mg s.c. QM compared with placebo s.c. QM in US Black/African American and Hispanic participants with established ASCVD and elevated levels of Lp(a) who are treated for cardiovascular (CV) risk factors according to local practice/guidelines for the reduction of cardiovascular risk.

Read the detailed description

CTQJ230A12303 is a randomized, double-blind, placebo-controlled, multi-center, Phase IIIb study to evaluate the efficacy ( measured by reduction of the Lp(a) levels) and safety of pelacarsen (TQJ230) 80mg s.c. QM compared to placebo in US Black/African American and US Hispanic participants, with established atherosclerotic cardiovascular disease (ASCVD) as evidenced by history of coronary heart disease, cerebrovascular disease or symptomatic peripheral artery disease (PAD) and elevated levels of Lp(a).

02

Conditions studied

  • Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease

Keywords

  • Elevated Lp(a)
  • Cardiovascular disease
  • Pelacarsen (TQJ230)
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 422 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female US Black/African American and US Hispanic participants 18 to ≤ 80 years of age
  • Lp(a) ≥ 125 nmol/L at the screening visit, measured at the Central laboratory
  • On Standard of Care (SoC) therapy for risk factors other than Lp(a), including LDL-C (LDL-C lowering therapy dose stable for at least 30 days), elevated blood pressure and diabetes, at the randomization visit according to local practice/guidelines.
  • Established ASCVD disease defined as documented:

    • Coronary heart disease (CHD) and/or
    • Cerebrovascular disease (CVD) and/or
    • Peripheral arterial disease (PAD):

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension
  • Heart failure (NYHA) class IV
  • History of of any organ system
  • History of hemorrhagic stroke or other major bleeding
  • count \<140,000 per mm3
  • Active liver disease or hepatic dysfunction
  • Significant kidney disease
  • Pregnant or nursing women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
422 participants (actual)

Study arms

  • Experimental
    TQJ230

    TQJ230 80mg QM s.c.

    Drug: TQJ230

  • Placebo comparator
    Placebo

    Matching placebo.

    Drug: Placebo

Interventions

  • DrugTQJ230

    TQJ230 80mg QM s.c.

    Also known as: pelacarsen

  • DrugPlacebo

    matching placebo

06

What researchers measure

Primary outcomes

  1. Change in log-transformed Lp(a) concentration from baseline at week 52

    The primary aim of the study is to demonstrate the superiority of pelacarsen to placebo in lowering the Lp(a) level at 12 months of treatment in US Black/African American and US Hispanic participants with established ASCVD and a Lp(a) level of ≥ 125 nmo/L.

    Time frame: Baseline, week 52

Secondary outcomes

  1. Incidence proportion of study discontinuations due to TEAEs

    Incidence proportion of study discontinuations due to TEAEs will be provided

    Time frame: Up to 52 weeks

  2. Incidence proportion of Treatment emergent adverse events (TEAEs) of special interest

    Incidence proportion of Treatment emergent adverse events (TEAEs) of special interest will be provided

    Time frame: Up to 52 weeks

07

Study locations

96 sites
  • Parkway Medical Center
    Birmingham, Alabama 35215, United States
  • Cardiology and Medicine Clinic PA
    Little Rock, Arkansas 72204, United States
  • National Heart Institute
    Beverly Hills, California 90211, United States
  • Alliance Clinical
    Canoga Park, California 91303, United States
  • Valley Clinical Trials Inc
    Covina, California 91723, United States
  • NICRs Research Center
    Garden Grove, California 92844, United States
  • University of Calif Irvine Med Cntr
    Irvine, California 92660, United States
  • Long Beach Clinical Trials
    Long Beach, California 90806, United States
  • Angel City Research Inc
    Los Angeles, California 90026, United States
  • California Medical Research Associates Inc
    Northridge, California 91324, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • Acclaim Clinical Research
    San Diego, California 92120, United States
  • Excel Medical Clinical Trials LLC
    Boca Raton, Florida 33434, United States
  • C and A Clinical Trials
    Cape Coral, Florida 33990, United States
  • Proactive Clinical Research
    Fort Lauderdale, Florida 33308, United States
  • National Research Institute
    Hialeah, Florida 33013, United States
  • Sister Life Research Inc
    Hialeah, Florida 33013, United States
  • Zenith Clinical Research
    Hollywood, Florida 33021, United States
  • Columbus Clinical Services LLC
    Miami, Florida 33125, United States
  • Finlay Medical Research
    Miami, Florida 33126, United States
  • Infinite Clinical Research
    Miami, Florida 33133, United States
  • Flourish Research Miami LLC
    Miami, Florida 33135, United States
  • International Research Associates LLC
    Miami, Florida 33156, United States
  • Baptist Health South
    Miami, Florida 33173, United States
  • A&A Research Group Inc
    Miami, Florida 33186, United States
  • Inpatient Research Clinical LLC
    Miami Lakes, Florida 33014, United States
  • FXM Clin Res Miramar LLC
    Miramar, Florida 33027, United States
  • CTMD Research
    Palm Springs, Florida 33406, United States
  • DBC Research USA
    Pembroke Pines, Florida 33029, United States
  • New Tampa Health
    Tampa, Florida 33603, United States
  • James A Haley Veterans Hospital
    Tampa, Florida 33612, United States
  • Cardiology Partners Clinical Research Institute
    Wellington, Florida 33449, United States
  • Flourish Research
    Winter Park, Florida 32789, United States
  • Morehouse School Of Medicine
    Atlanta, Georgia 30310, United States
  • Atlanta Heart Specialists LLC
    Tucker, Georgia 30084, United States
  • Synexus Clinical Research US Inc
    Chicago, Illinois 60602, United States
  • Chicago Clinical Research Inst
    Chicago, Illinois 60607, United States
  • Cardiovascular Associates Research
    Covington, Louisiana 70433, United States
  • Omega Clinical Research
    Metairie, Louisiana 70006, United States
  • CV Ins of the South
    Opelousas, Louisiana 70570, United States
  • Monroe Research Llc
    West Monroe, Louisiana 71291, United States
  • Southern Clin Research Clinic
    Zachary, Louisiana 70791, United States
  • Sinai Ct for Throm Res and Drug Dev
    Baltimore, Maryland 21209, United States
  • Ascension Saint Agnes Heart Care
    Baltimore, Maryland 21229, United States
  • Johns Hopkins Univ School of Med
    Baltimore, Maryland 21287, United States
  • Metropolitan Cardiovascular Consultants Llc
    Beltsville, Maryland 20705, United States
  • Johns Hopkins University
    Columbia, Maryland 21044, United States
  • Anderson Medical Research
    Ft. Washington, Maryland 20744, United States
  • Capitol Cardiology Associates
    Lanham, Maryland 20706, United States
  • MD Medical Research
    Oxon Hill, Maryland 20745, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Aa Mrc Mhs
    Flint, Michigan 48503, United States
  • Aa Mrc Llc
    Flint, Michigan 48504, United States
  • Elite Clinical Research LLC
    Jackson, Mississippi 39202, United States
  • Stern Cardiovascular Foundation Inc
    Southaven, Mississippi 38671, United States
  • Las Vegas Endocrinology
    Henderson, Nevada 89074, United States
  • AB Clinical Trials
    Las Vegas, Nevada 89119, United States
  • Clinical Research of South Nevada
    Las Vegas, Nevada 89121, United States
  • Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
  • Overlook Medical Center
    Summit, New Jersey 07901, United States
  • Jamaica Hospital Medical Center
    Richmond Hill, New York 11418, United States
  • Monroe Biomedical Research
    Monroe, North Carolina 28112, United States
  • Alliance Medical Ministry
    Raleigh, North Carolina 27610, United States
  • Velocity Clin Research Springdale
    Cincinnati, Ohio 45246, United States
  • NexGen Research
    Lima, Ohio 45801, United States
  • Care Access Research
    Easton, Pennsylvania 18045, United States
  • TCV Clinical Studies
    Linwood, Pennsylvania 19061, United States
  • The Stern Cardiovascular Foundation
    Germantown, Tennessee 38138, United States
  • Apex Cardiology Research Associates of Jackson
    Jackson, Tennessee 38301, United States
  • Plano Primary Care Clinic
    Allen, Texas 75002-3688, United States
  • Pharma Tex Research
    Amarillo, Texas 79106, United States
  • North Hills Medical Research Inc
    Bedford, Texas 76021, United States
  • SW Family Medicine Associates
    Dallas, Texas 75235, United States
  • David Turbay MD PLLC
    El Paso, Texas 79905, United States
  • Ctr for Clin Rsch and Innovatn
    Houston, Texas 77008, United States
  • Angiocardiac Care of Texas PA
    Houston, Texas 77025, United States
  • Dallas Heart and Vascular Consultants PA
    Houston, Texas 77084, United States
  • Epic Clinical Research
    Lewisville, Texas 75057, United States
  • The Heart Institute of East Texas
    Lufkin, Texas 75904, United States
  • Discovery Clinical Trials
    Pflugerville, Texas 78660-3015, United States
  • University of Texas Health Science Ctr
    San Antonio, Texas 78229-3900, United States
  • Clinical Trials of Texas
    San Antonio, Texas 78229, United States
  • Sugar Lakes Family Practice
    Sugar Land, Texas 77479, United States
  • Javara Research
    Alexandria, Virginia 22311, United States
  • Virginia Heart
    Falls Church, Virginia 22042, United States
  • Heart Care Associates P C
    Hopewell, Virginia 23860, United States
  • Dominion Medical Associates
    Richmond, Virginia 23219, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298-0111, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • Advanced Clinical Research LLC
    Bayamón, 00959, Puerto Rico
  • Dr Yolanda Figueroa Private Pr
    Humacao, 00791, Puerto Rico
  • CAIMED Center
    Ponce, 00716, Puerto Rico
  • Research and Cardiovascular Corp
    Ponce, 00717-1322, Puerto Rico
  • Latin Clinical Trial Center Inc
    San Juan, 00909, Puerto Rico
  • VA Caribbean Healthcare System
    San Juan, 00921, Puerto Rico
  • Advance Medical Research Center
    San Juan, 00926, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Mar 2026, 23 months.

Of 42 industry-sponsored phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 79. This study's 23 months is below that.

Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2024
First posted
Feb 20, 2024
StartActual
Apr 24, 2024
Primary completionActual
Mar 25, 2026
CompletionActual
Mar 25, 2026
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06267560
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Apr 24, 2024
Primary completion
Mar 25, 2026
Completion
Mar 25, 2026
Last update
Aug 10, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pelacarsen

Start the discussion